Skip to main content
SpringerLink
Log in

HIV

  • Chapter
  • First Online:
Managing Psychosexual Consequences in Chronic Diseases

  • 128 Accesses

Abstract

Acquired immunodeficiency syndrome (AIDS) is a life-threatening chronic condition caused by the human immunodeficiency virus (HIV). HIV infection continues to be a major public health issue with an estimated 38 million people living with HIV at the end of 2019, worldwide [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. https://www.unaids.org/en/resources/fact-sheet. Accessed 11 May 2021.

  2. Azevedo-Pereira JM, Santos-Costa Q. HIV interaction with human host: HIV-2 as a model of a less virulent infection. AIDS Rev. 2016;18(1):44–53.

    PubMed  Google Scholar 

  3. Campbell-Yesufu OT, Gandhi-Perrin RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis. 2011;52(6):780–7. https://doi.org/10.1093/cid/ciq248.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Santoro MM, Perno CF. HIV-1 genetic variability and clinical implications. ISRN Microbiol. 2013;2013:481314. https://doi.org/10.1155/2013/481314.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Yamaguchi J, Vallari A, McArthur C, Sthreshley L, Cloherty GA, Berg MG, Rodgers MA. Brief report: complete genome sequence of CG-0018a-01 establishes HIV-1 subtype L. J Acquir Immune Defic Syndr. 2020;83(3):319–22. https://doi.org/10.1097/QAI.0000000000002246.

    Article  PubMed  Google Scholar 

  6. CRFs. https://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html. Accessed 11 May 2021.

  7. Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell. 1986;44(6):941–7. https://doi.org/10.1016/0092-8674(86)90017-6.

    Article  CAS  PubMed  Google Scholar 

  8. Kao SY, Calman AF, Luciw PA, Peterlin BM. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature. 1987;330(6147):489–93. https://doi.org/10.1038/330489a0.

    Article  CAS  PubMed  Google Scholar 

  9. Karn J, Stoltzfus CM. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med. 2012;2(2):a006916. https://doi.org/10.1101/cshperspect.a006916.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Asamitsu K, Okamoto T. The Tat/P-TEFb protein-protein interaction determining transcriptional activation of HIV. Curr Pharm Des. 2017;23(28):4091–7. https://doi.org/10.2174/1381612823666170710164148.

    Article  CAS  PubMed  Google Scholar 

  11. Asamitsu K, Fujinaga K, Okamoto T. HIV Tat/P-TEFb interaction: a potential target for novel anti-HIV therapies. Molecules. 2018;23(4):933. https://doi.org/10.3390/molecules23040933.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nekhai S, Jeang K-T. Transcriptional and post-transcriptional regulation of HIV-1 gene expression: role of cellular factors for Tat and Rev. Future Microbiol. 2006;1(4):417–26. https://doi.org/10.2217/17460913.1.4.417.

    Article  CAS  PubMed  Google Scholar 

  13. Donahue DA, Kuhl BD, Sloan RD, Wainberg MA. The viral protein Tat can inhibit the establishment of HIV-1 latency. J Virol. 2012;86(6):3253–63. https://doi.org/10.1128/JVI.06648-11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kumar A, Herbein G. The macrophage: a therapeutic target in HIV-1 infection. Mol Cell Ther. 2014;2:10. https://doi.org/10.1186/2052-8426-2-10.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kamori D, Ueno T. HIV-1 Tat and viral latency: what we can learn from naturally occurring sequence variations. Front Microbiol. 2017;8:80. https://doi.org/10.3389/fmicb.2017.00080.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Khoury G, Darcis G, Lee MY, Bouchat S, Van Driessche B, Purcell DFJ, Van Lint C. Adv Exp Med Biol. 2018;1075:187–212. https://doi.org/10.1007/978-981-13-0484-2_8.

    Article  CAS  PubMed  Google Scholar 

  17. Hendricks CM, Cordeiro T, Gomes AP, Stevenson M. The interplay of HIV-1 and macrophages in viral persistence. Front Microbiol. 2021;12:646447. https://doi.org/10.3389/fmicb.2021.646447. eCollection 2021.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Emery A, Swanstrom R. HIV-1: to splice or not to splice, that is the question. Viruses. 2021;13(2):181. https://doi.org/10.3390/v13020181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med. 2011;364(20):1943–54. https://doi.org/10.1056/NEJMra1011874.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17(13):1871–9. https://doi.org/10.1097/00002030-200309050-00005.

    Article  PubMed  Google Scholar 

  21. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339(1):33–9. https://doi.org/10.1056/NEJM199807023390107.

    Article  CAS  PubMed  Google Scholar 

  22. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med. 1997;102(5B):117–24. https://doi.org/10.1016/s0002-9343(97)00077-6.

    Article  CAS  PubMed  Google Scholar 

  23. Ling AE, Robbins KE, Brown TM, Dunmire V, Thoe SY, Wong SY, Leo YS, Teo D, Gallarda J, Phelps B, Chamberland ME, Busch MP, Folks TM, Kalish ML. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA. 2000;284(2):210–4. https://doi.org/10.1001/jama.284.2.210.

    Article  CAS  PubMed  Google Scholar 

  24. Kopko PM, Fernando LP, Bonney EN, Freeman JL, Holland PV. HIV transmissions from a window-period platelet donation. Am J Clin Pathol. 2001;116(4):562–6. https://doi.org/10.1309/GBLA-NL8D-3277-XUP1.

    Article  CAS  PubMed  Google Scholar 

  25. Lindbäck S., Thorstensson R., Karlsson AC, von Sydow M., Flamholc L., Blaxhult A., Sönnerborg A., Biberfeld G., Gaines H. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS 2000; 14(15): 2333-2339. doi: https://doi.org/10.1097/00002030-200010200-00014.

    Book  Google Scholar 

  26. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, Chesney M, Anderson J, Levy J, Kahn JO. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;16(8):1119–29. https://doi.org/10.1097/00002030-200205240-00005.

    Article  PubMed  Google Scholar 

  27. Holodniy M, Busch M. Establishing the diagnosis of HIV infection. In: Dolin R, Masur H, Saag M, editors. AIDS therapy. 2nd ed. New York: Churchill Livingstone; 2002. p. 3–20.

    Google Scholar 

  28. Nguyen KA, Busch MP. Evolving strategies for diagnosing human immunodeficiency virus infection. Am J Med. 2000;109(7):595–7. https://doi.org/10.1016/s0002-9343(00)00611-2.

    Article  CAS  PubMed  Google Scholar 

  29. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, Self SG, Borrow P. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83(8):3719–33. https://doi.org/10.1128/JVI.01844-08.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. Viral dynamics of acute HIV-1 infection. J Exp Med. 1999;190(6):841–50. https://doi.org/10.1084/jem.190.6.841.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Buttò S, Raimondo M, Fanales-Belasio E, Suligoi B. Suggested strategies for the laboratory diagnosis of HIV infection in Italy. Ann Ist Super Sanita. 2010;46(1):34–41. https://doi.org/10.4415/ANN_10_01_05.

    Article  PubMed  Google Scholar 

  32. Bangham CRM. CTL quality and the control of human retroviral infections. Eur J Immunol. 2009;39(7):1700–12. https://doi.org/10.1002/eji.200939451.

    Article  CAS  PubMed  Google Scholar 

  33. Koup RA. Virus escape from CTL recognition. J Exp Med. 1994;180(3):779–82. https://doi.org/10.1084/jem.180.3.779.

    Article  CAS  PubMed  Google Scholar 

  34. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68(9):6103–10. https://doi.org/10.1128/JVI.68.9.6103-6110.1994.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, Bangham CR, Phillips RE. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A. 1997;94(5):1890–5. https://doi.org/10.1073/pnas.94.5.1890.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Prins HAB, Verbon A, Boucher CAB, Rokx C. Ending the epidemic: critical role of primary HIV infection. Neth J Med. 2017;75(8):321–7.

    CAS  PubMed  Google Scholar 

  37. Vanhems P, Lambert J, Cooper DA, Perrin L, Carr A, Hirschel B, Vizzard J, Kinloch-de LS, Allard R. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis. 1998;26(2):323–9. https://doi.org/10.1086/516289.

    Article  CAS  PubMed  Google Scholar 

  38. Rosenberg YJ, Anderson AO, Pabst R. HIV-induced decline in blood CD4/CD8 ratios: viral killing or altered lymphocyte trafficking? Immunol Today. 1998;19(1):10–7. https://doi.org/10.1016/s0167-5699(97)01183-3.

    Article  CAS  PubMed  Google Scholar 

  39. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, Cohen D, Robbins GK, Pae E, Alter G, Wurcel A, Stone D, Rosenberg ES, Walker BD, Altfeld M. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med. 2004;200(6):701–12. https://doi.org/10.1084/jem.20041270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Douek DC. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev. 2003;5(3):172–7.

    PubMed  Google Scholar 

  41. Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian R, Valdez H. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 2003;17(14):2015–23. https://doi.org/10.1097/00002030-200309260-00002.

    Article  PubMed  Google Scholar 

  42. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee T-H, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR. Ann Intern Med. 2014;161(5):319–27. https://doi.org/10.7326/M14-1027.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Ford ES, Puronen CE, Sereti I. Immunopathogenesis of asymptomatic chronic HIV infection: the calm before the storm. Curr Opin HIV AIDS. 2009;4(3):206–14. https://doi.org/10.1097/COH.0b013e328329c68c.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. 2009;15(8):866–70. https://doi.org/10.1038/nm.1949.

    Article  CAS  PubMed  Google Scholar 

  45. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I. The utility of ADCC responses in HIV infection. Curr HIV Res. 2008;6(6):515–9. https://doi.org/10.2174/157016208786501472.

    Article  CAS  PubMed  Google Scholar 

  46. Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther. 2009;9(1):55–69. https://doi.org/10.1517/14712590802571928.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Saksena NK, Rodes B, Wang B, Soriano V. Elite HIV controllers: myth or reality? AIDS Rev. 2007;9:195–207.

    PubMed  Google Scholar 

  48. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200(6):749–59. https://doi.org/10.1084/jem.20040874.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200(6):761–70. https://doi.org/10.1084/jem.20041196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections–going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009;48(5):609–11. https://doi.org/10.1086/596756.

    Article  PubMed  Google Scholar 

  51. Clifford GM, Franceschi S. Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol. 2009;5(5):669–78. https://doi.org/10.2217/fon.09.28.

    Article  CAS  PubMed  Google Scholar 

  52. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94(24):13193–7. https://doi.org/10.1073/pnas.94.24.13193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295–300. https://doi.org/10.1126/science.278.5341.1295.

    Article  CAS  PubMed  Google Scholar 

  54. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278(5341):1291–5. https://doi.org/10.1126/science.278.5341.1291.

    Article  CAS  PubMed  Google Scholar 

  55. Bartlett AW, Williams PCM, Jantarabenjakul W, Kerr SJ. State of the mind: growing up with HIV. Paediatr Drugs. 2020;22(5):511–24. https://doi.org/10.1007/s40272-020-00415-1.

    Article  PubMed  Google Scholar 

  56. UNAIDS: Combination HIV prevention: tailoring and coordinating biomedical, behavioural and structural strategies to reduce new HIV infections A UNAIDS discussion paper. 2010. https://www.unaids.org/sites/default/files/media_asset/JC2007_Combination_Prevention_paper_en_0.pdf. Accessed 11 May 2021.

  57. Moretti S, Cafaro A, Tripiciano A, Picconi O, Buttò S, Ensoli F, Sgadari C, Monini P, Ensoli B. HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. Expert Rev Vaccines. 2020;19(1):71–84. https://doi.org/10.1080/14760584.2020.1712199.

    Article  CAS  PubMed  Google Scholar 

  58. Semple SJ, Zians J, Strathdee SA, et al. Sex marathons and methamphetamine use among HIV-positive men who have sex with men. Arch Sex Behav. 2009;38:583.

    Article  PubMed  Google Scholar 

  59. AMMAR. Creating a research and development agenda for rectal microbicides that protect against HIV infection: seminar report. 2003. http://www.microbicide.org/microbicideinfo/reference/amfar.report.on.rectal.microbicides.pdf. Accessed 24 January 2007.

  60. Worth H, Zablotska I. Associations between crystal methamphetamine use and potentially dangerous sexual activity among gay men in Australia. Arch Sex Behav. 2007;36:646–54.

    Article  PubMed  Google Scholar 

  61. Shoptaw S, Reback CJ, Freese TE. Patient characteristics, HIV serostat and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and addiction in Los Angeles. J Addict Dis. 2002;21:91–105.

    Article  PubMed  Google Scholar 

  62. Sullivan MC, Cruess DG, Huedo-Medina TB, et al. Substance use, HIV serostat disclosure, and sexual risk behavior in people living with HIV: an event-level analysis. Arch Sex Behav. 2020;49:2005–18.

    Article  PubMed  Google Scholar 

  63. Bird JD, Eversman M, Voisin DR. “You can’t trust everyone”: the impact of sexual risk, partner type, and perceived partner reliability on HIV disclosure decisions among HIV-positive black gay and bisexual men. Cult Health Sex. 2017;19(8):829–43.

    Article  PubMed  Google Scholar 

  64. Horvath KJ, Lammert S, Martinka A, et al. Definizione del rischio sessuale nell’era della prevenzione biomedica dell’HIV: implicazioni per la ricerca e la pratica sull’HIV. Arch Sex Behav. 2020;49:91–102.

    Article  PubMed  Google Scholar 

  65. Ning C, Huang J, Liang H. Pre-exposure prophylaxis for the prevention of HIV infection in high-risk populations: a meta-analysis of randomized controlled trials. PLoS ONE. 2014;9(2):e87674. https://doi.org/10.1371/journal.pone.0087674.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of transmission of HIV through condomless sex in serodifferent gay couples with HIV-positive partner receiving suppressive antiretroviral therapy (PARTNER): final results of a prospective, multicentre observational study. Lancet. 2019;393:2428–38.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Benotsch EG, Kalichman S, Cage M. Men who met sexual partners via the Internet: prevalence, predictors, and implications for HIV prevention. Arch Sex Behav. 2002;31:177–83.

    Article  PubMed  Google Scholar 

  68. Zapata JP, Dang M, Quinn KG, et al. COVID-19 related disruptions in HIV testing and prevention among young sexual minority men aged 17-24: a qualitative study using synchronous online focus groups, April-September 2020. Arch Sex Behav. 2022;51:303–14.

    Article  PubMed  Google Scholar 

  69. Andersson GZ, Reinius M, Eriksson LE, Svedhem V, Esfahani FM, Deuba K, Rao D, Lyatuu GW, Giovenco D, Ekstrom AM. Stigma-reducing interventions in people living with HIV to improve health-related quality of life. HIV Lancet. 2020;7(2):e129–40. https://doi.org/10.1016/s2352-3018(19)30343-1.

    Article  Google Scholar 

  70. Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, Del Amo Valero J, Gatell JM, Baptista-Leite R, Mendao L, Porter K, Vella S, Rockstroh JK. Beyond HIV viral suppression: the new frontier of quality of life. BMC Med. 2016;14(1):94. https://doi.org/10.1186/s12916-016-0640-4.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Quinn K, Bowleg L, Dickson-Gomez J. Fear of being black plus fear of being gay: the effects of intersectional stigma on PrEP use among young black gay, bisexual and other men who have sex with men. Soc Sci Med. 2019;232:86–93.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Mgbako O, Benoit E, Iyengar NS, Kuhner C, Brinker D, Duncan DT. “Like a time bomb”: the persistence of trauma in the HIV diagnosis experience among black men having sex with men in New York City. BMC Public Health. 2020;20(1):1–14. https://doi.org/10.1186/s12889-020-09342-9.

    Article  Google Scholar 

  73. Logie CH, James L, Tharao W, Loutfy MR. “We don’t exist”: a qualitative study of the marginalization experienced by HIV-positive, lesbian, bisexual, queer and transgender women in Toronto, Canada. J Int AIDS Soc. 2012;15(2):17392. https://doi.org/10.7448/ias.15.2.17392.

    Article  PubMed  Google Scholar 

  74. Johnson Shen M, Freeman R, Karpiak S, Brennan-Ing M, Seidel L, Siegler EL. The intersectionality of stigmas among key HIV-infected older populations: a thematic analysis. Clin Gerontol. 2019;42(2):37–149.

    Article  Google Scholar 

  75. Logie CH, James L, Tharao W, Loutfy MR. We do not exist: a qualitative study on the marginalization experienced by HIV-positive lesbian, bisexual, queer and transgender women in Toronto, Canada. 2012. https://doi.org/10.7448/IAS.15.2.17392.

  76. Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N. Estimating HIV prevalence and risk behaviors of transgender people in the United States: a systematic review. Behav Against AIDS. 2008;12(1):1–17.

    Article  Google Scholar 

  77. Javanbakht M, Ragsdale A, Shoptaw S, Gorbach PM. Transactional sex among men who have sex with men: differences in substance use and HIV status. Urban Health J. 2019;96:429–41.

    Article  Google Scholar 

  78. Walters SM, Rivera AV, Reilly KH, Anderson BJ, Bolden B, Wogayehu A, Braunstein S. Sex swapping between people injecting drugs in the New York metropolitan area: the importance of local context, gender, and sexual identity. AIDS Behav. 2018;22(9):2773–87.

    Article  PubMed  Google Scholar 

  79. Bond KT, Yoon IS, Houang ST, Downing MJ, Grov C, Hirshfield S. Transactional sex, substance use, and sexual risk: earnings direction comparison for a us sample of men who have sex with men based on the internet. Res Sex Soc Policy. 2019;16:255–67.

    Article  Google Scholar 

  80. Nerlander LM, Hess KL, Sionean C, Rose C, Thorson A, Broz D, Paz-Bailey G. Sex swapping and HIV infection among men who have sex with men: 20 US cities, 2011. AIDS Behav. 2017;8:2283–94.

    Article  Google Scholar 

  81. Friedman MR, Dodge BM. The role of syndemics in explaining health disparities among bisexual men: a blueprint for a theoretically informed perspective. In: Understanding the HIV/AIDS epidemic in the United States. Cham: Springer; 2016. p. 71–98.

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. “Surveillance and Pathogenesis of HIV Variants and Associated Co-infections”-National Center for HIV/AIDS Research-Istituto Superiore di Sanità, Roma, Italy

    Stefano Buttò

  2. Department of Sexual Medical Center, San Raffaele Hospital, Milano, Italy

    Elena Vittoria Longhi

Authors
  1. Stefano Buttò
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Vittoria Longhi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano Buttò .

Editor information

Editors and Affiliations

  1. Department of Sexual Medical Center, San Raffaele Hospital, Milano, Italy

    Elena Vittoria Longhi

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Buttò, S., Longhi, E.V. (2023). HIV. In: Longhi, E.V. (eds) Managing Psychosexual Consequences in Chronic Diseases. Springer, Cham. https://doi.org/10.1007/978-3-031-31307-3_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-31307-3_36

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-31306-6

  • Online ISBN: 978-3-031-31307-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation